



General Meeting 6 May 2025

# Important information and disclaimer

The information contained in this document (“Presentation”) has been prepared by Gelion plc (the “Company”) solely for information purposes and does not purport to be comprehensive or contain all the information that may be required by recipients to evaluate the Company. This Presentation and the information contained in it has not been independently verified and no reliance should be placed on it or the opinions contained within it.

While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as “Information”) and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

The contents of this Presentation have not been approved by any person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended (“FSMA”). Reliance on this Presentation for the purpose of engaging in investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Any person in the United Kingdom who is in any doubt about the subject matter to which this Presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

# Important information and disclaimer

Recipients of this Presentation outside the United Kingdom should inform themselves about and observe any applicable legal restrictions in their jurisdiction which may be relevant to the distribution, possession or use of this Presentation and recognise that the Company does not accept any responsibility for contravention of any legal restrictions in such jurisdiction.

This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

# Q&A



# Resolutions

# Ordinary Resolution

1. To authorise the directors to allot shares in relation to the Fundraising as set out in the Circular.

Resolution	In Favour		Discretion		Against		Withheld
	Votes	%	Votes	%	Votes	%	Votes
1	49,953,988	99.99	0	0	723	0.01	496

# Special Resolution

2. To authorise the directors to dis-apply statutory pre-emption rights in respect of any allotment of shares pursuant to Resolution 1.

Resolution	In Favour		Discretion		Against		Withheld
	Votes	%	Votes	%	Votes	%	Votes
2	49,939,638	99.99	0	0	1,929	0.01	13,640



# Thank you